Markets closed

Novo Nordisk A/S

NVO · NYSE

Analyst Consensus

Hold

13 analysts

$45

Current

—

Low

$47

Average

—

High

Average target implies +4.42% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Hold across 13 analysts. The only disclosed target statistic is a mean of 46.5; both the low and high are unavailable, so the target cluster and spread cannot be quantified. No named analyst is identified as the most or least bullish, and the evidence does not document any target or rating revisions during the past week. The substantive disagreement is therefore visible in the research framing rather than attributable to individual analysts: bears emphasize slowing injectable GLP-1 momentum, pricing headwinds, competition and the failed ZEUS cardiovascular endpoint, while the bullish case rests on Novo’s leadership in diabetes and obesity treatments and its promising GLP-1 pipeline. The mean target is above the latest close, but no range is supplied.

Rating Actions

No individual rating actions have been captured for NVOyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

CANTOR FITZGERA

EXANE BNP PARIB

GUGGENHEIM SEC.

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

MORGAN STANLEY

SANFORD BERNSTE

STIFEL NICOLAUS

TD COWEN

UBS

Symbol: NVO
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: NYSE

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Key Issues

Bullish view

Novo Nordisk has several promising GLP-1 medicines in its pipeline and is described as a leader in diabetes and obesity treatments, giving it assets to sustain the franchise.

Bearish view

Zacks identifies slowing injectable GLP-1 momentum, pricing headwinds and fierce competition as near-term problems, while Lilly’s competing Mounjaro and Zepbound franchise is attracting investor attention.